SCHEDULE 13G/A: Paradigm BioCapital Reports 3.3% Stake in Cidara Therapeutics

Paradigm BioCapital Advisors LP and related entities have reported a 3.3% beneficial ownership stake in Cidara Therapeutics, Inc. as of September 30, 2025.

Summary

• Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, and Senai Asefaw, M.D. collectively reported beneficial ownership of 961,164 shares of Cidara Therapeutics, Inc. common stock, representing 3.3% of the class.
• Paradigm BioCapital International Fund Ltd. separately reported beneficial ownership of 848,515 shares, representing 2.9% of the class.
• The reported ownership percentages are based on 29,335,397 shares of Common Stock outstanding as of September 30, 2025, as disclosed by Cidara Therapeutics in its Form 10-Q filed on November 6, 2025.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating a passive investment purpose, not for changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: This is a routine beneficial ownership report (Schedule 13G Amendment) indicating a passive investment below the 5% threshold for the primary fund, and 3.3% for the overall group. It does not convey significant positive or negative sentiment regarding the company's performance or prospects.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Cidara Therapeutics, Inc.'s future performance or strategic direction.

Industry Context

This Schedule 13G filing indicates a passive investment by an institutional investor in a biotechnology company. Such filings are routine disclosures required when an entity acquires more than 5% of a company's stock (or amends a previous filing), signaling a long-term, non-controlling interest. For Cidara Therapeutics, a biopharmaceutical company, institutional ownership can provide stability and validation, though this specific filing reports ownership below the initial 5% threshold for the fund itself, and 3.3% for the broader group.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding significant institutional ownership, which can be a factor in assessing investor confidence and liquidity.
• Company Management: Awareness of significant passive investors can influence strategic decisions, though this filing explicitly states no intent to influence control.

Key Dates

Keywords

Cidara Therapeutics, Paradigm BioCapital, Beneficial Ownership, Schedule 13G, Common Stock, Investment Management, Biotechnology, Pharmaceuticals